Driving forces for Antacids Market

The effects of gastroesophageal reflux disease (GERD) - According to the National Library of Medicine 2022 report, 783.95 million persons had GERD in 2019. The need for antacids is rising in proportion to the number of persons suffering with GERD. Because of their many benefits, antacids are considered the best treatment for acidity. People know that antacids provide rapid relief, and the fact that they are easily accessible is helping to drive the antacid market expansion.

Shifting demographics as a result of an increase in the elderly population - Due to their ability to provide immediate relief from acidity, antacids are becoming increasingly important to the elderly population. As a result, they frequently purchase or use antacids to treat these stomach problems. One could argue that antacid sales globally are higher in countries with higher rates of aging populations. According to a 2022 World Health Organization (WHO) report, 1 in 6 people will be 60 years of age or older by 2030 and 2050. In addition, there will be 2.1 billion people over 60 in the world in 2020, up from 1.4 billion.

North America Antacids Market

Because of the rising prevalence of gastroesophageal reflux disease (GERD) and changes in American lifestyles that are causing gastrointestinal issues, the antacid industry in North America is predicted to expand rapidly.

The demand for over-the-counter digestive products like antacids is rising due to the trend of self-medication in North American nations like the United States. Additionally, product approval is a key factor driving market expansion. For example, Zydus Lifesciences received final approval from the US Food and Drug Administration (FDA) in June 2022 to sell 20 and 40 mg strengths of famotidine tablets. Famotidine is a histamine H2 receptor blocker. It works by reducing the amount of acid produced by the stomach. The market under research is expected to grow significantly over the forecast period as a consequence of the aforementioned factors.

Additionally, a March 2022 article in the Annals of the Esophagus states that 10–20% of Americans suffer from GERD symptoms on a weekly basis, accounting for almost 40% of the country's population. It is expected that the high prevalence of GERD in the nation will support regional market expansion overall.

Antacids Company Overview

The leading market players in the Antacids market are Abbott Laboratories, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble Company, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited.

Antacids Company News

• In March 2024, the digestion brand ENO, which was formerly owned by GSK Consumer Healthcare and is currently a part of Haleon, unveiled a new item named "ENO Chewy Bites." There are two flavors of these chewable antacids: Tangy Lemon and Zesty Orange. With this announcement, ENO's product line is expanded to give customers more choices for conveniently and pleasantly controlling stomach discomfort.
• In March 2023, WonderbellyTM, a company that specializes in clean ingredients and medications for digestive health, introduced its Wonderbelly AntacidTM chewable tablets.

Drug Class – Market in 4 Viewpoints:

1. Proton Pump Inhibitors
2. H2 Antagonist
3. Acid Neutralizers
4. Pro-Motility Agents

Formulation Type – Market in 4 Viewpoints:

1. Tablets
2. Liquid
3. Powder
4. Others

Distribution Channel – Market in 3 Viewpoints:

1. Retail Pharmacy
2. Hospital Pharmacy
3. Online Pharmacy

Geography – Global Antacids Market

North America

1. United States
2. Canada

Europe

1. France
2. Germany
3. Italy
4. Spain
5. United Kingdom
6. Belgium
7. Netherlands
8. Turkey

Asia Pacific

1. China
2. Japan
3. India
4. Australia
5. South Korea
6. Thailand
7. Malaysia
8. Indonesia
9. New Zealand

Latin America

1. Brazil
2. Mexico
3. Argentina

Middle East & Africa

1. South Africa
2. Saudi Arabia
3. United Arab Emirates

Company Insights:

• Overviews
• Recent Developments
• Revenue

Company Analysis:

1. Abbott Laboratories
2. AstraZeneca plc
3. Bayer AG
4. Boehringer Ingelheim International GmbH
5. Reddy’s Laboratories Ltd.
6. GlaxoSmithKline plc
7. Johnson & Johnson
8. Pfizer Inc.
9. Procter & Gamble Company
10. Sanofi S.A.
11. Sun Pharmaceutical Industries Ltd.
12. Takeda Pharmaceutical Company Limited

Report Details: